Significance of interleukin-27 expression in the intestinal mucosa of patients with inflammatory bowel disease

World Chinese Journal of Digestology

Volumn 18, Issue 1, 2010, Pages 39-43

  Cui, Yi ^a   Liu, Zhan Ju ^b   Zhao, Zhi Guo ^a   Zheng, Peng Yuan ^a   Huang, De Feng ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Cytokine; Inflammatory bowel disease; Interleukin 27; Intestinal mucosa

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 27; INTERLEUKIN 27 P28 SUBUNIT; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE MUCOSA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; UPREGULATION; WESTERN BLOTTING;

EID: 77749255729     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v18.i1.39     Document Type: Article

References (22)

1. Gismera CS, Aladrén BS. Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing? World J Gastroenterol 2008; 14: 5491-5498
2. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1419-1423
3. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429
5. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, Mizuguchi J, Yoshimoto T. A role for IL-27 in early regulation of Th1 differentiation. J Immunol 2005; 175: 2191-2200
6. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-2231
7. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, Yoshimoto T. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 7317-7324
8. Li CS, Zhang Q, Lee KJ, Cho SW, Lee KM, Hahm KB, Choi SC, Yun KJ, Chung HT, Chae SC. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean populat ion. J Gastroenterol Hepatol 2009; 24: 1692-1696
9. Chinese source
10. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 2008; 67: 1474-1479
11. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008; 180: 6527-6535
12. Chinese source
13. Shen W, Durum SK. Synergy of IL-23 and Th17 Cytokines: New Light on Inflammatory Bowel Disease. Neurochem Res 2009 Nov 14. [Epub ahead of print]
14. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mat tson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal Malefyt R, Rennick D, Kastelein RA. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-790
15. Carl JW, Bai XF. IL27: Its Roles in the Induction and Inhibition of Inflammation. Int J Clin Exp Pathol 2008; 1: 117-123
16. Villarino AV, Larkin J 3rd, Saris CJ, Caton AJ, Lucas S, Wong T, de Sauvage FJ, Hunter CA. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol 2005; 174: 7684-7691
17. Villarino AV, Artis D, Bezbradica JS, Miller O, Saris CJ, Joyce S, Hunter CA. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int Immunol 2008; 20: 739-752
18. Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J, Nakani shi K. IL-2 7 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007; 179: 4415-4423
19. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, Yoshimura A, Yoshida H. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 2006; 177: 5377-5385
20. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 16-23
21. Scheller J, Schuster B, Hölscher C, Yoshimoto T, Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun 2005; 326: 724-728
22. Artis D, Villarino A, Silverman M, He W, Thornton EM, Mu S, Summer S, Covey TM, Huang E, Yoshida H, Koretzky G, Goldschmidt M, Wu GD, de Sauvage F, Miller HR, Saris CJ, Scott P, Hunter CA. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol 2004; 173: 5626-5634